GUIDE-ITBiomarker-Guided Heart Failure Therapy Using NT-proBNP

Study start date: December 1, 2012

Inclusion Criteria: Age 18 years or older Most recent LVEF to be ≤ 40% by any method within 12 months of randomization. High risk heart failure as defined by the following criteria: A Heart Failure Event in the prior 12 months, defined as any one of the following: HF Hospitalization Treatment in the Emergency Department (or equivalent) for Heart Failure Outpatient treatment for heart failure with intravenous diuretics AND NT-proBNP greater than 2000 pg/mL or BNP greater than 400 pg/mL at any time during the 30 days prior to randomization Willing to provide informed consent Exclusion Criteria: Acute coronary syndrome (clinical diagnosis) or cardiac revascularization procedure within 30 days Cardiac resynchronization therapy (CRT) within prior 3 months or current plan to implant CRT device Active myocarditis, Hypertrophic obstructive cardiomyopathy, pericarditis, or restrictive cardiomyopathy Severe stenotic valvular disease Anticipated heart transplantation or ventricular assist device within 12 months Chronic inotropic therapy Complex congenital heart disease End stage renal disease with renal replacement therapy Non cardiac terminal illness with expected survival less than 12 months Women who are pregnant or planning to become pregnant Inability to comply with planned study procedures Enrollment or planned enrollment in another clinical trial